Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | The impact of clonal features on the survival of patients with non-cardiac AL amyloidosis

Paolo Milani • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, comments on the impact of clonal features on the diagnosis, overall survival (OS), and hematologic event-free survival (EFS) of patients with non-cardiac AL amyloidosis, and highlights the importance of using this information to guide treatment decisions. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Janssen

More from Paolo Milani

3:14
The impact of amyloid deposits in AL amyloidosis
Paolo Milani • 22 Nov 2023
4:27
The unmet needs in AL amyloidosis and limitations of the current SoC
Paolo Milani • 22 Nov 2023
4:01
Dara-based regimens vs CyBorD in patients with AL amyloidosis & stage IIIb cardiac involvement
Paolo Milani • 22 Nov 2023
1:08
The clinical features of pulmonary light chain amyloidosis
Paolo Milani • 8 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals